Charles Lu

AbbVie (United States)

Papers

2

Total Citations

12

H-Index

2

About

Charles Lu is a molecular biology researcher whose work sits at the cutting edge of functional genomics and CRISPR-based screening technologies. His research focuses on optimizing genome-wide loss-of-function (LOF) screens, with a particular emphasis on harnessing the power of CRISPR systems to uncover novel gene functions across a wide range of physiological and pathophysiological contexts. Lu's most notable contribution centers on the development and refinement of AsCas12a-based genome-wide CRISPR screens paired with multi-guide arrays — an innovative approach designed to overcome critical limitations inherent in conventional CRISPR-Cas9 libraries, such as incomplete gene coverage and off-target effects. By engineering more efficient and precise screening platforms, his work has the potential to dramatically accelerate the discovery of gene-disease relationships and therapeutic targets. His 2023 publication on this topic has already garnered 10 citations, signaling growing recognition within the functional genomics community. For students and researchers working in gene editing, cancer biology, or drug target discovery, Lu's methodological advances represent an important toolkit for conducting more reliable and comprehensive genome-scale investigations.

Research Focus

Key Achievements

2
H-Index
2
Papers
12
Total Citations
6
Avg Citations/Paper
🏆 Most Cited Paper
Optimization of Genomewide CRISPR Screens Using AsCas12a and Multi-Guide Arrays
10 citations · 2023
📈 Most Prolific Year: 2023 (1 Papers)
🤝 Key Collaborators: 8
🏛 Institutions: AbbVie (United States)

Top Papers

  1. 1
  2. 2

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 14 days ago